Showing 3951-3960 of 5646 results for "".
- Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapieshttps://modernod.com/news/ray-therapeutics-closes-oversubscribed-100m-series-a-financing-to-advance-optogenetic-gene-therapies/2481621/Ray Therapeutics announced an upsized and oversubscribed $100 million Series A financing round to advance multiple programs targeting blinding diseases through clinical development. Ray Therapeutics has developed an optogenetic platform to bioengineer a pipeline of g
- Invirsa Completes Enrollment of Phase 1/2a Dry Eye Studyhttps://modernod.com/news/invirsa-completes-enrollment-of-phase-12a-dry-eye-study/2481619/Invirsa announced that its first clinical trial, a phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa's topically administered eye drop formulation of INV-102, has completed enrollment. Subjects had moderate dry eye and dosing was well tol
- Researchers Discover Small-Molecule Drugs with Potential Clinical Utility in the Treatment of Retinal Diseaseshttps://modernod.com/news/researchers-discovere-small-molecule-drugs-with-potential-clinical-utility-in-the-treatment-of-retinal-diseases/2481616/In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP). The study, titled, “
- C. Light Receives FDA Clearance for Retinal Eye Movement Monitor, Retitrackhttps://modernod.com/news/c-light-receives-fda-clearance-for-retinal-eye-movement-monitor-retitrack/2481615/C. Light Technologies announced it has received 510(k) clearence from the FDA for the Retitrack, which is designed to provide new understanding and insight into oculomotor function via the retina, providing concrete and objective metrics to medical professionals. The
- Oculus Incorporates New Subsidiary in Indiahttps://modernod.com/news/oculus-incorporates-new-subsidiary-in-india/2481614/Oculus has incorporated Oculus Medical Devices India as its 12th international subsidiary as of May 1, 2023. Located in Mumbai, Oculus India, aims to provide cutting-edge medical equipment to the Indian market while maintaining the high standards and quality that Oculus is known for. Sr
- New Museum of the Eye Exhibit Explores the Eye as a Cultural Symbol, From Ancient to Modern Timeshttps://modernod.com/news/new-museum-of-the-eye-exhibit-explores-the-eye-as-a-cultural-symbol-from-ancient-to-modern-times/2481612/Truhlsen-Marmor Museum of the Eye, the world’s only free, public museum dedicated to the science of sight, announced the opening of "Decoding the Eye: Signs and Symbols," a new exhibit exploring how the eye appears as a symbol throughout time. The exhibit will run from May 2023 to
- International Ophthalmology Panel Calls for Recognizing and Treating Childhood Myopia as a Diseasehttps://modernod.com/news/international-ophthalmology-panel-calls-for-recognizing-and-treating-childhood-myopia-as-a-disease/2481607/Responding to one of the greatest eye health issues in a generation, nine internationally recognized pediatric ophthalmologists have come together to call for greater recognition of childhood myopia as a disease and earlier treatment of children. Their perspectives are now available as a white pa
- Eyenovia Receives FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasishttps://modernod.com/news/eyenovia-receives-fda-approval-of-mydcombi-the-first-ophthalmic-spray-for-mydriasis/2481603/Eyenovia announced that the FDA has approved Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first approved fixed dose combinatio
- Formosa and AimMax Submit NDA to the FDA for APP13007 for Postoperative Inflammation and Pain After Ocular Surgeryhttps://modernod.com/news/formosa-and-aimmax-announce-the-nda-submission-to-the-fda-for-app13007-for-postoperative-inflammation-and-pain-following-ocular-surgery/2481602/Formosa Pharmaceuticals and AimMax Therapeutics announced the submission of a new drug application to the FDA for APP13007, a novel aqueous nanosuspension formulation of the corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain following ocular surger
- Glaukos Announces FDA Acceptance of NDA Submission for iDose TRhttps://modernod.com/news/glaukos-announces-fda-acceptance-of-nda-submission-for-idose-tr/2481599/Glaukos announced it has received the “Day 74” notification from the FDA acknowledging the previously submitted new drug application (NDA) for iDose TR (travoprost intraocular implant) is sufficiently complete to permit a substantive review. The Prescription Drug U